Tinnitus is a phantom auditory perception that occurs in humans. Tinnitus, which is a distressing problem affecting many people around the world, is commonly referred to as ringing in the ears. No effective drug therapy is available for this elusive disease, although much research work into mechanism and possible treatment is underway. As yet, there are no Food and Drug Administration approved drugs available and the quest for a new treatment option for tinnitus focus on important challenges in tinnitus management. A number of options have been used to treat patients with tinnitus, but outcomes have been limited. A new, curative modality will provide a turning point in the management of tinnitus. The purpose of this review article is to discuss the pathophysiology, global burden, current treatment, and prevention of tinnitus, with future prospective studies in new drug therapy for this elusive condition.

Introduction: Chronic suppurative otitis media (CSOM) is a common problem in worldwide and untreated CSOM leads to fatal complications like facial nerve paralysis, lateral sinus thrombosis, labyrinthitis, meningitis and brain abscess in developing country like India.Objective: To isolate causative bacteria and antibiotic sensitivity pattern for CSOM and to know the prevalence of extended spectrum beta lactamases (ESBL) and Metallobetalactamases (MBL) in CSOM patients.Methods: A total of 500 ear swabs of clinical suspected CSOM patients were cultured on specific cultured medium and identified the bacteria with conventional methods. Then all the identified bacteria were subjected with specific antibiotics by the Kirby–Bauer's method to know the resistance pattern of antibiotics. ESBL and MBL strains were detected by double disc diffusion test.Results: A total of 384 bacteria were isolated from 500 CSOM patients, among them 86 P. aeruginosa (22.40%), 112 Staphylococcus aureus (29.17%), 53 A. baumannii (13.80%), 32 E. aerogenes (18%), 26 C. freundii (6.77%), 24 K. oxytoca (6.25%), 23 P. vulgaris (5.99%), 18 K. pneumoniae (4.69%) and 10 P. mirabilis (2.60%) identified with conventional methods. From antibiotic disc diffusion methods 74.22% ESBL strains and 9.90% MBL strains were documented. Multidrug resistant strains of P. aeruginosa (86/384,22.40%) were more prevalent than those of S. aureus (112/384,29.17%) and other bacteria in ear discharges. Imipenem and vancomicin could control to gram negative bacteria and gram positive bacteria respectively.Conclusion: Continuous and periodic evaluation of microbiological profile and antimicrobial sensitivity pattern of bacterial is essential for optimum management of CSOM patients.

Introduction: Benign paroxysmal positional vertigo (BPPV) is a common cause of vertigo.BPPV is often overlooked by general physician and treated with anti-vertigo drugs. Objective: To evaluate the prevalence, incidence, clinical presentation of benign paroxysmal positional vertigo (BPPV). Also assessing the age, gender and site of the lesion, association with other vestibular disorders, progression, and recurrence in these patients. Materials and methods: A retrospective study of total of 172patients those attended in vertigo clinic for giddiness diagnosed as BPPV. Data analyzed from medical records since last 3 years. Out of total 685 vertigo patients in our Vertigo Clinic, 172were found to suffer from BPPV.The age of the patients ranged from 23 years to 76 years with mean of 41.4 year. Results: Out of 685 patients with vertigo,172 were diagnosed as BPPV. Among them, 102 female and 70 male patients. The posterior canal was affected in 81.97 %, the lateral in 10.46 %, the anterior in 5.23 % and multiple canals in 2.32 %.The treatment maneuver used most was Epley’smaneuver. Recurrence was observed in 10.37 % of the cases. It was idiopathic in 73.83% of cases. Conclusion: BPPV is a common peripheral vestibular disorder causing significant morbidity, psychosocial impact and medical costs. Epley’s maneuver provides rapid relief of symptoms of BPPV. In addition daily Brandt–Daroff exercises decrease the chances of recurrence rate.